Insider · CIK 0001585669

Vanover Kimberly E.

Reports to the SEC for 1 company · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001585669

Forms 4 and 5

Insider transactions

38 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2019-01-08	Intra-Cellular Therapies, Inc.Stock Option (right to buy)A Award	SVP, Early Stage Clinical Dev.	AAward	+81K sh	—	—	80,951
2019-01-08	Intra-Cellular Therapies, Inc.Restricted Stock UnitsA Award	SVP, Early Stage Clinical Dev.	AAward	+58.9K sh	—	—	58,915
2019-01-07	Intra-Cellular Therapies, Inc.S Sale	SVP, Early Stage Clinical Dev.	SSale	−592 sh	$12.29	−$7,275.68	27,068
2019-01-04	Intra-Cellular Therapies, Inc.M Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	+1,554 sh	—	—	37,224
2019-01-04	Intra-Cellular Therapies, Inc.S Sale	SVP, Early Stage Clinical Dev.	SSale	−7,380 sh	$11.37	−$83.9K	29,844
2019-01-04	Intra-Cellular Therapies, Inc.S Sale	SVP, Early Stage Clinical Dev.	SSale	−2,184 sh	$11.81	−$25.8K	27,660
2019-01-04	Intra-Cellular Therapies, Inc.Restricted Stock UnitsM Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	−1,554 sh	—	—	0
2019-01-03	Intra-Cellular Therapies, Inc.M Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	+2,649 sh	—	—	19,510
2019-01-03	Intra-Cellular Therapies, Inc.M Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	+16.2K sh	—	—	35,670
2019-01-03	Intra-Cellular Therapies, Inc.Restricted Stock UnitsM Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	−2,649 sh	—	—	2,649
2019-01-03	Intra-Cellular Therapies, Inc.Restricted Stock UnitsM Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	−16.2K sh	—	—	32,320
2019-01-02	Intra-Cellular Therapies, Inc.S Sale	SVP, Early Stage Clinical Dev.	SSale	−4,834 sh	$11.10	−$53.7K	16,861
2018-12-31	Intra-Cellular Therapies, Inc.A Award	SVP, Early Stage Clinical Dev.	AAward	+9,322 sh	—	—	21,695
2018-01-05	Intra-Cellular Therapies, Inc.S Sale	SVP, Early Stage Clinical Dev.	SSale	−1,185 sh	$17.37	−$20.6K	13,145
2018-01-04	Intra-Cellular Therapies, Inc.M Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	+1,554 sh	—	—	14,330
2018-01-04	Intra-Cellular Therapies, Inc.Restricted Stock UnitsM Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	−1,554 sh	—	—	1,554
2018-01-03	Intra-Cellular Therapies, Inc.M Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	+2,648 sh	—	—	12,776
2018-01-03	Intra-Cellular Therapies, Inc.Restricted Stock UnitsM Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	−2,648 sh	—	—	5,298
2018-01-03	Intra-Cellular Therapies, Inc.Stock Option (right to buy)A Award	SVP, Early Stage Clinical Dev.	AAward	+65.2K sh	—	—	65,164
2018-01-03	Intra-Cellular Therapies, Inc.Restricted Stock UnitsA Award	SVP, Early Stage Clinical Dev.	AAward	+48.5K sh	—	—	48,480
2017-01-05	Intra-Cellular Therapies, Inc.S Sale	SVP, Early Stage Clinical Dev.	SSale	−800 sh	$16.59	−$13.3K	10,128
2017-01-04	Intra-Cellular Therapies, Inc.M Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	+1,553 sh	—	—	10,928
2017-01-04	Intra-Cellular Therapies, Inc.Restricted Stock UnitsM Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	−1,553 sh	—	—	3,108
2017-01-03	Intra-Cellular Therapies, Inc.Stock Option (right to buy)A Award	SVP, Early Stage Clinical Dev.	AAward	+31.9K sh	—	—	31,858
2017-01-03	Intra-Cellular Therapies, Inc.Restricted Stock UnitsA Award	SVP, Early Stage Clinical Dev.	AAward	+7,946 sh	—	—	7,946
2016-12-15	Intra-Cellular Therapies, Inc.M Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	+5,000 sh	$1.36	+$6,800	5,000
2016-12-15	Intra-Cellular Therapies, Inc.S Sale	SVP, Early Stage Clinical Dev.	SSale	−2,500 sh	$15.26	−$38.2K	2,500
2016-12-15	Intra-Cellular Therapies, Inc.M Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	+10K sh	$1.50	+$15K	12,500
2016-12-15	Intra-Cellular Therapies, Inc.S Sale	SVP, Early Stage Clinical Dev.	SSale	−5,000 sh	$15.19	−$76K	7,500
2016-12-15	Intra-Cellular Therapies, Inc.M Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	+3,750 sh	$1.50	+$5,625	11,250
2016-12-15	Intra-Cellular Therapies, Inc.S Sale	SVP, Early Stage Clinical Dev.	SSale	−1,875 sh	$15.28	−$28.6K	9,375
2016-12-15	Intra-Cellular Therapies, Inc.Stock Option (right to buy)M Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	−5,000 sh	—	—	0
2016-12-15	Intra-Cellular Therapies, Inc.Stock Option (right to buy)M Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	−10K sh	—	—	0
2016-12-15	Intra-Cellular Therapies, Inc.Stock Option (right to buy)M Exercise/Conversion	SVP, Early Stage Clinical Dev.	MExercise/Conversion	−3,750 sh	—	—	0
2016-01-04	Intra-Cellular Therapies, Inc.Stock Option (right to buy)A Award	SVP, Early Stage Clinical Dev.	AAward	+19.7K sh	—	—	19,653
2016-01-04	Intra-Cellular Therapies, Inc.Restricted Stock UnitA Award	SVP, Early Stage Clinical Dev.	AAward	+4,661 sh	—	—	4,661
2015-01-02	Intra-Cellular Therapies, Inc.Stock Option (right to buy)A Award	SVP, Early Stage Clinical Dev.	AAward	+72.1K sh	—	—	72,120
2014-06-30	Intra-Cellular Therapies, Inc.Stock Option (right to buy)A Award	SVP, Early Stage Clinical Dev.	AAward	+100K sh	—	—	100,000

Recent filings

Accepted (ET)
Jan 84
Vanover Kimberly E.0001209191-19-002957
SEC(opens sec.gov)
Jan 34
Vanover Kimberly E.0001209191-19-001588
SEC(opens sec.gov)
Jan 54
Vanover Kimberly E.0001209191-18-002599
SEC(opens sec.gov)

Companies

Intra-Cellular Therapies, Inc.SVP, Early Stage Clinical Dev.

Address

C/O INTRA-CELLULAR THERAPIES, INC. 3960 BROADWAY

NEW YORK, NY, 10032